NCT02623972View on ClinicalTrials.gov

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 26, 2016

Primary Completion Date

May 31, 2021

Study Completion Date

December 31, 2026

Conditions
Inflammatory Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions
DRUG

Eribulin

administered IV for 4 cycles

DRUG

Adriamycin

administered IV with cyclophosphamide for 4 cycles

DRUG

Cyclophosphamide

administered IV with adriamycin for 4 cycles

Trial Locations (2)

02215

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER